Written question asked by Julian Lewis (Conservative) on Tuesday, 28 October 2025, in the House of Commons. It was due for an answer on Monday, 3 November 2025 (named day). It was answered by Sarah Jones (Labour) on Tuesday, 4 November 2025 on behalf of the Home Office.
Psilocybin
- Question
-
To ask the Secretary of State for the Home Department, whether she has recently received representations from the (a) Advisory Council on the Misuse of Drugs, (b) Royal College of Psychiatrists and (c) Department of Health on the potential clinical use of psilocybin under controlled conditions to treat serious psychiatric illness.
- Answer
-
No recent representations on the potential clinical use of psilocybin to treatpsychiatric illness have been made to the Home Office by the AdvisoryCouncil on the Misuse of Drugs, Royal College of Psychiatrists or theDepartment of Health and Social Care.
The Government recognises that studies into the potential use of psilocybinas part of the treatment for mental health conditions have been or are being conducted in the UK under Home Office licence.
On 16 July, the Government responded to recommendations from theAdvisory Council on the Misuse of Drugs (ACMD) on how best to reducebarriers to clinical research with Schedule 1 drugs, such as psilocybin.
Secondary information
- Type
- Written question
- Reference
- 85687
- Session
- 2024-26
- Subjects
- Mental illness Advisory Council on the Misuse of Drugs Department of Health and Social Care Royal College of Psychiatrists Psilocybin
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2025-11-04 15:37:25 +0000
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-26/85687
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-26/85687
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-26/85687